Valuation: Aradigm Corporation

Market Cap 4.89M 4.35M 4.03M 3.65M 6.87M 463M 6.98M 48.27M 18.98M 242M 18.32M 17.94M 773M P/E 2016
-0.72x
P/E 2017 -9.3x
Enterprise Value 12.8M 11.39M 10.55M 9.57M 17.99M 1.21B 18.28M 126M 49.71M 634M 48M 47.01M 2.02B EV / Sales 2016
73.3x
EV / Sales 2017 7.27x
Free-Float
60.28%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+6.73% - - 702K
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.15%+30.95%+43.43% 43.76B
+3.87%+9.73%+21.52%+142.33% 42.09B
+7.91%+1.34%+263.31%+577.76% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +2.79%+1.13%+52.90%+121.07% 37.58B
Weighted average by Cap. +3.05%+0.62%+51.69%+122.72%

Financials

2016 2017
Net sales 195K 174K 161K 146K 274K 18.48M 279K 1.93M 757K 9.67M 731K 716K 30.84M 14.46M 12.87M 11.92M 10.81M 20.34M 1.37B 20.66M 143M 56.18M 717M 54.26M 53.13M 2.29B
Net income -32.94M -29.32M -27.15M -24.62M -46.31M -3.12B -47.04M -325M -128M -1.63B -124M -121M -5.21B -10.7M -9.53M -8.82M -8M -15.05M -1.01B -15.29M -106M -41.58M -531M -40.15M -39.32M -1.69B
Net Debt -9.37M -8.34M -7.72M -7.01M -13.18M -888M -13.39M -92.61M -36.4M -465M -35.15M -34.42M -1.48B 7.91M 7.04M 6.52M 5.91M 11.13M 750M 11.3M 78.19M 30.74M 392M 29.68M 29.06M 1.25B
Logo Aradigm Corporation
Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
Employees
-
  1. Stock Market
  2. Stocks
  3. ARDMQ Stock